相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2004
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Nucleus Network has acquired Hammersmith Medicines Research (HMR), establishing the only early-phase clinical research provider with dedicated facilities across Australia, the United States, and the United Kingdom. - The acquisition creates a fully integrated global platform that enables studies to commence in one regulatory environment and seamlessly transition to another, accelerating timelines and reducing operational risk. - The combined organization expands access to broader and more diverse volunteer and patient populations, supporting faster recruitment and more inclusive study designs critical for first-in-human and adaptive trial protocols. - With over 20 years of experience and more than 1,500 first-in-human studies conducted, the expanded network strengthens capabilities for delivering early-phase clinical trials across three continents.
- Sen-Jam Pharmaceutical's SJP-001, an over-the-counter therapeutic, has received ethics approval for a clinical trial in Australia. - The trial, conducted by Nucleus Network and supported by Novotech, will assess SJP-001's efficacy and safety in modulating inflammation and improving metabolic outcomes. - SJP-001 targets metabolic health and aims to provide relief from overindulgence in food and drink by affecting inflammatory pathways. - This approval marks a significant step for SJP-001 in becoming a globally accessible, non-immunosuppressive solution for inflammation.
- The ACCC is concerned that Blackstone's acquisition of I'rom Group could substantially lessen competition in the Australian phase 1 clinical trial market. - The merger would combine Nucleus Network (Blackstone) and CMAX Clinical Research (I'rom), the two largest phase 1 clinical trial service providers in Australia. - The ACCC fears the acquisition may lead to lower service quality and higher prices for customers due to reduced competition. - Blackstone's ownership of Precision Medicine Group raises concerns about potential restrictions on access to phase 1 trial services for competing contract research organizations.
